We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 7,655

Regulatory Developments Life Sciences Companies Should Expect in the New Presidential Administration
  • Jones Day
  • USA
  • January 20 2017

2017 and beyond promises to be a time for continued evolution and uncertainty for life sciences companies doing business in the United States. In


Supreme Court Updates - Intellectual Property Weekly Abstracts - Week of January 16, 2017
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

The Supreme Court of Canada announced that judgment in this application for leave to appeal will be delivered on Thursday, January 19, 2017. The


Dismissed Motion for Interlocutory Injunction Upheld on Appeal
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

This was an appeal against Justice Manson's unreported decision in 2016 FC 606, dismissing TearLab's motion for an interlocutory injunction to prevent


'Visually negligible' is definite enough
  • Baker Donelson Bearman Caldwell & Berkowitz PC
  • USA
  • January 18 2017

The Federal Circuit recently determined that the patent claim term 'visually negligible' was definite enough to meet the definiteness requirement


Patent and Pharma Update - January 2017
  • Herbert Smith Freehills LLP
  • European Union, United Kingdom
  • January 18 2017

The UPC may be open for business in 2017 despite Brexit The last six months have been eventful following the UK's June 2016 referendum vote to


Arnold J refers question to the CJEU on Article 3(d) of the SPC Regulation and calls for clarifications on past CJEU jurisprudence
  • Bristows LLP
  • European Union, United Kingdom
  • January 18 2017

In a judgment handed down at the end of last week, Arnold J has indicated his intention to make a reference to the CJEU concerning the interpretation


Application for Prohibition Granted for Generic Version of Concerta
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

The Court granted Janssen's application prohibiting the Minister of Health from issuing an NOC to Actavis for its generic version of Concerta. The


Summary of FDA Guidance on the Nonproprietary Naming of Biological Products
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • January 18 2017

On January 12, 2017, the U.S. Food and Drug Administration (“FDA”) released a final Guidance for Industry, Nonproprietary Naming of Biological


Patent Validity and Infringement Upheld on Appeal; Limitation Period in Patent Act not Necessarily Applicable to Old Act Patents
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

In this case, the FCA considered an appeal and cross-appeal of a decision relating to omeprazole. The trial decision can be found here (2015 FC 322


Supreme Court to Consider Biologics Price Competition and Innovation Act
  • Kramer Levin Naftalis & Frankel LLP
  • USA
  • January 17 2017

On Friday, Jan. 13, the Supreme Court granted the appellant's petition and the respondent's cross-petition for a writ of certiorari in Sandoz Inc. v